Investors who Lost Money on Intellia Therapeutics, Inc. (NTLA) Should Contact Levi & Korsinsky About Pending Class Action - NTLA
Portfolio Pulse from
Levi & Korsinsky law firm has filed a class action securities lawsuit against Intellia Therapeutics (NTLA) alleging securities fraud between July 30, 2024 and January 8, 2025. The lawsuit claims the company misled investors about its NTLA-3001 study and failed to disclose the declining demand for viral-based editing. On January 9, 2025, Intellia announced a major reorganization, halting NTLA-3001 research and reducing workforce by 27%, causing the stock price to drop from $12.02 to $10.20.
April 10, 2025 | 12:30 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Intellia Therapeutics stock is likely to experience continued negative pressure due to the class action lawsuit and the company's strategic shift away from NTLA-3001 research.
The lawsuit and company's reorganization announcement suggest significant investor uncertainty, potential financial penalties, and reduced market confidence in Intellia's research strategy.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100